The overall goal of the field of cancer molecular pathology is the identification, analysis, and application of molecular markers relevant to cancer susceptibility, diagnosis, prognosis, monitoring, or therapy. As this young interdisciplinary field grows and evolves, there is a clear need to develop novel mechanisms to provide customized training experiences for postdoctoral physician-scientists. These training experiences need to provide a strong educational background that stresses the interrelationships among the participating disciplines that include tumor biology, pathology, oncology, genetics, and quantitative biology. Furthermore, such training experiences must provide in-depth exposure to an interdisciplinary research environment that requires interactive collaboration among biologists, pathologists, oncologists, and other specialists. To create this important training mechanism at the University of Pennsylvania, the Department of Pathology and Laboratory Medicine in conjunction with the University of Pennsylvania Cancer Center is proposing the implementation of a Cancer Molecular Pathology Training Program. The objective of this training program is to permit individuals with clinical training in pathology, oncology, or related fields to obtain basic education and develop research skills necessary for the validation and translation of cancer molecular information into clinical tests for cancer risk assessment, screening, diagnosis, prognosis, minimal disease assessment and therapeutic response prediction. These interdisciplinary didactic and research experiences will be facilitated by organization of a program faculty consisting of tumor biologists, pathologists, oncologists, molecular geneticists, and quantitative biologists. Trainees of this program will be prepared for an academic career in cancer molecular pathology by: 1) coursework in a specialized curriculum; 2) research training that involves completion of an interdisciplinary research project under the supervision of multiple mentors from the participating disciplines; and 3) publication, presentation and grantsmanship training. This innovative program will build on the considerable existing strengths at the University of Pennsylvania in pathology, genetics and cancer, with an established environment of interdisciplinary interactions among the Department of Pathology and Laboratory Medicine, the Cancer Center, the Center for Clinical Epidemiology and Biostatistics and other academic units.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Education Projects (R25)
Project #
5R25CA087812-06
Application #
7123849
Study Section
Subcommittee G - Education (NCI)
Program Officer
Myrick, Dorkina C
Project Start
2001-06-06
Project End
2008-05-31
Budget Start
2006-06-01
Budget End
2008-05-31
Support Year
6
Fiscal Year
2006
Total Cost
$174,805
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Ahn, Eun Hyun; Mercado, Gabriela E; LaƩ, Marick et al. (2013) Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Oncol Rep 30:968-78
Mercado, Gabriela E; Xia, Shujuan J; Zhang, Chune et al. (2008) Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer 47:510-20
Mercado, Gabriela E; Barr, Frederic G (2007) Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med 7:47-61
Chang, John T; Palanivel, Vikram R; Kinjyo, Ichiko et al. (2007) Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315:1687-91
Amaravadi, Ravi K; Yu, Duonan; Lum, Julian J et al. (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117:326-36
Lae, M; Ahn, E H; Mercado, G E et al. (2007) Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 212:143-51
Mercado, Gabriela E; Barr, Frederic G (2005) Looking downstream of sarcoma-associated chimeric transcription factors: when is a target really a target? Cancer Biol Ther 4:456-8
Hingorani, Sunil R; Wang, Lifu; Multani, Asha S et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-83
Amaravadi, Ravi; Thompson, Craig B (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115:2618-24
Singhal, Sunil; Kyvernitis, Chris G; Johnson, Steven W et al. (2003) Microarray data simulator for improved selection of differentially expressed genes. Cancer Biol Ther 2:383-91

Showing the most recent 10 out of 16 publications